NR082, a gene therapy drug candidate for the treatment of Leber hereditary optic neuropathy, was granted orphan drug designation by the European Medicines Agency, according to a press release from ...
"Leber's Hereditary Optic Neuropathy (LHON) Market Insight, Epidemiology And Market Forecast - 2032" The Leber Hereditary Optic Neuropathy market in the 7MM is set for strong growth, driven by ...
NEWARK, Del., Sept. 24, 2020 /PRNewswire/ -- Neurophth Therapeutics, Inc., (hereinafter referred to as "Neurophth") today announced that its leading candidate, NR082 (rAAV2-ND4, NFS-01 project), was ...
Sudden onset of optic neuropathy in the elderly is most frequently vascular in aetiology; however, when bilateral, the diagnosis of LHON should still be considered. We report the oldest documented ...
A significant improvement of visual acuity was reported in eyes treated with a unilateral intravitreal injection of lenadogene nolparvovec for Leber hereditary optic neuropathy, researchers reported ...
Leber's Hereditary Optic Neuropathy (LHON) is a subacute form of blindness that develops in early adulthood. Found to occur in males at least 4-5 times more commonly, it is painless and bilateral, ...
FDA grants Priority Review to idebenone for Leber Hereditary Optic Neuropathy (LHON), a disease for which there are no existing approved treatments in the U.S.; action date of February 28, 2026 PARMA, ...
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/hwz37s/lebers) has announced the addition of the "Leber's Hereditary Optic ...
Elamipretide has also been granted Fast Track designation for treating primary mitochondrial myopathy (PMM) - which gained Orphan Drug Designation in September - and Barth syndrome Stealth ...
For those living with an inherited form of blindness that comes on suddenly, a one-time injection could be life-changing. Leber's hereditary optic neuropathy (LHON) is a rare cause of blindness that ...
People living with LHON suffer from rapid and severe loss of central vision due to mitochondrial dysfunction of retinal ganglion cells. 1 The submission was based on the safety and efficacy data from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback